Tunneled Pleural Catheters for Refractory Effusions Attributed to Congestive Heart Failure (TREAT-CHF) Trial
Key facts
- Who runs it
- University of California, Los Angeles
- Where
- Los Angeles, United StatesSee the site
- Trial code
- Status
- Withdrawn
- Started
- 1 Oct 2020
- Ended
- 1 Oct 2025
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- tunneled pleural catheter
- Record updated
- 5 April 2023
- Why it stopped
- Lack of enrollment
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 18 criteriaShow less
Who can take part
- Age > 18 years of age at enrollment
- Able to give consent
- Documented heart failure defined by echocardiography demonstrating depressed left ventricular ejection fraction and/or left ventricular diastolic dysfunction
- Recurrent and symptomatic pleural effusions refractory to medical management
- Maximal medical management will be determined by the referring provider a. This should include use of at least three of the classes of medications that are standard of care for heart failure: i. Angiotensin converting enzyme inhibitor or angiotensin receptor blockers ii. Beta blockers iii. Loop diuretics iv. Potassium-sparing diuretics b. If the patient is not on at least three drugs from the above classes, documentation of drug intolerance must be present
- Documented subjective symptomatic relief after thoracentesis and drainage of the pleural space
- Pleural fluid clinically determined to be due only to CHF
- Pleural fluid analysis consistent with transudate or pseudoexudate a. Transudate: defined by Light's criteria, all of the following must occur, i. Pleural:serum lactate dehydrogenase (LDH) < 0.6 ii. Pleural LDH < 2/3 x upper limit of normal of serum LDH iii. Pleural:serum protein < 0.5 b. Pseudoexudate: defined by all of the following, i. Pleural:serum LDH > 0.6 but < 1 ii. Pleural:serum protein < 0.5 iii. Serum-pleural protein gradient > 3.2 and/or serum-pleural albumin gradient > 1.2
- Anticipated outpatient management
Who cannot take part
- Heart transplant candidate
- Lone right sided heart failure with normal left sided cardiac function
- Active malignancy
- Active pulmonary infection
- Imminent death within 1 month
- Alternate etiology for pleural effusion origin
- On hemodialysis during enrollment
- Exudative pleural effusion, defined as any effusion that dose not meet criteria for transudate or pseudoexudate
- Contraindication for TPC insertion
Where in United States
- UCLA Medical CenterLos Angeles, United States
About the trial
What the trial wants to find out
Congestive heart disease (CHF) can frequently cause transudative pleural effusions, some of which do not completely resolve with diuretics alone. These effusions can cause significant morbidity, leading to ongoing dyspnea and hypoxia, resulting in additional office and hospital visits. TREAT-CHF is a randomized trial studying tunneled pleural catheter (TPC) versus standard medical management for the treatment recurrent symptomatic pleural effusions secondary to CHF that are refractory to maximal medical therapy. TREAT-CHF will study whether the addition of a TPC can improve quality of life and minimize health care utilization over the one year following insertion.
The 2 groups in the trial
- Intervention GroupTreatment being tested
This group will receive placement of a tunneled pleural catheter to drain their recurrent, chronic, and symptomatic pleural effusion in addition to their usual medication therapy.
Treatment: tunneled pleural catheter
- Usual CareNo study treatment, for comparison
The control group will continue with medical therapy by their referring physician and serial thoracenteses when clinically appropriate.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 5 April 2023